Background
==========

Spinal muscular atrophy (SMA) is an autosomal recessive neurodegenerative childhood disease characterized by loss of lower motor neurons in the anterior horn cells in the spinal cord and brainstem, causing progressive proximal symmetrical weakness and atrophy of skeletal muscle. It is the most common inherited neuromuscular diseases of childhood with a prevalence of 1 in 6,000 to 10,000 \[[@B1],[@B2]\]. SMA has been classified clinically into four types based on age of onset and maximum function attained \[[@B3]\]. Type I SMA, Werdnig-Hoffmann disease, is characterized by onset within the first 6 months of age, and the children never achieve the ability to sit without support. Type II SMA is characterized by onset of muscle weakness and hypotony usually after six months of age; the children are able to sit but unable to walk unaided. In the type III SMA, Kugelberg-Welander disease, the initial manifestations usually occurs after 18 months of age; and the patients achieves the ability to walk. Type IV SMA is a mild form with an adult onset of muscle weakness. All four types of SMA show a progressive course, which is severe in type I and mild in type III and IV SMA \[[@B4]\].

Approximately 95%-98% of individuals with a clinical diagnosis of SMA lack exon 7 in both copies of *SMN1*gene, while approximately 2%-5% of them are compound heterozygotes for deletion of *SMN1*in one allele and an intragenic mutation of *SMN1*in another allele \[[@B5],[@B6]\]. The human *SMN*gene is located at the chromosome 5 (5q), and exists in two copies, *SMN1*and *SMN2*. *SMN1*is the telomeric copy and produces a full-length survival motor neuron (SMN) protein necessary for a normal lower motor neuron function \[[@B5]\]. The centromeric *SMN2*copy mostly encodes a protein that is lacking in exon 7 due to alternative splicing, thereby producing a less stable protein. The amount of functional SMN protein produced by *SMN2*is not sufficient to prevent the progressive degeneration of motor neuron when *SMN1*is absent. The *SMN2*gene copy number is variable, ranging from zero to five. Several studies have demonstrated a strong inverse correlation between the number of *SMN2*copies and SMA severity \[[@B7]-[@B11]\]. The presence of three or more copies of *SMN2*is correlated with a milder phenotype \[[@B9]-[@B11]\]. Thus, *SMN2*activation and/or modulation of the *SMN2*splicing pattern have been used as a strategy for SMA treatment to increase full length SMN protein level.

The modulation of *SMN2*expression is in part controlled by acetylation and deacetylation of histones in the promoter region. Thus, the inhibitors of histone deacetylases (HDAC), such as phenylbutyrate and valproic acid (VPA), could promote the acetylation of the DNA increasing the gene expression and the level of full-length SMN protein \[[@B12]\]. Many studies have demonstrated that phenylbutyrate, a drug used in the treatment of urea acid cycle disorders, and VPA increase *SMN2*transcripts and full-length SMN protein in different types of cells from patients and in animal models of SMA \[[@B13]-[@B16]\]. Preliminary clinical trials have studied the preclinical stages of research in animal models or in vitro experiments \[[@B17]-[@B22]\]. Brichta et al \[[@B17]\] observed an increase of 13 times in the blood level of full length SMN proteins in seven SMA children treated with VPA. An improvement in seven adult patients with SMA type III and IV during treatment with VPA was reported by Weihl et al \[[@B18]\]. Tsai et al \[[@B19]\] observed significant increase of the overall strength in type II SMA treated with VPA during six months. In an open label study, Swoboda et al \[[@B20]\] assessed 42 SMA individuals treated with VPA during 12 months, and observed a significant improvement almost restricted to participants aged less than 5 years. More recently, Swoboda et al \[[@B21]\] assessed 61 subjects randomized 1:1 to placebo or treatment with VPA and L-carnitine for six months, but no benefit was demonstrated. Thus, the clinical efficacy of VPA in patients with SMA is still controversial. In this study, we quantified the muscular strength and motor function of patients with SMA type II and III treated with VPA and assessed the side effects of the medication.

Methods
=======

Study design
------------

We included in this study 35 patients with SMA type II and III confirmed by molecular analysis, aged between 2 to 18 years old, regularly treated at the Out-patient Service Center for Neuromuscular Disorders and Child Neurology at our Institution. This open, comparative and longitudinal study had the approval of the Ethical Committee for Project and Research; and the parents or legal guardians signed an informed consent form for participating in the study. The patients were evaluated five times during one year by the same examiners: PGP (physician) and IAD (physical therapist). The first evaluation was done just before the prescription of VPA, and the following assessments were carried out at three, six, nine and twelve months after the onset of VPA therapy. All patients received 20 mg/Kg/day of VPA (divided into 2 or 3 doses), L-Carnitine (100 mg/Kg/day) and vitamin supplement. Laboratory tests were performed before the beginning of the treatment and after 6 and 12 months, and included the measurement of blood cells, hepatic and pancreatic enzymes and serum level of VPA.

Muscular strength and functional assessment
-------------------------------------------

Patients were evaluated using the following methods: 1) The Hammersmith Functional Motor Scale (HFMS), which includes 20 items scored from 0 to 40 \[[@B23]\]; 2) the Medical Research Council (MRC) method for testing the muscular strength of the main muscular groups (flexion and extension of shoulders, hips, elbows, wrists, knees, feet and trunk; abduction and adduction of shoulders and hip), scored from 0 to 5 points \[[@B24]\]; and 3) the Barthel Index for evaluating the daily activities in patients older than 5 years of age \[[@B25]\].

### Statistical analysis

We used the ANOVA test to compare both the averages by time and groups. The Pearson product-moment correlation coefficient was calculated with its interval at 95% (IC 95%) to analyze the relation between the interested variables.

Results
=======

Among the thirty-five patients with SMA, five did not return regularly to the appointments and eight did not take the drug according to the medical prescription. Thus, only 22 patients, aged between 2 and 18 years (mean = 5.5), 14 SMA type II (63.6%) and 8 type III (36.4%), completed the period of the study (Table [1](#T1){ref-type="table"}). In all 22 patients the serum concentration of VPA was between 40-100 mg/dL in the period of the study. No patient displayed any significant change in laboratory tests performed during the period of follow-up. Five patients developed a worsening of prior hand tremors, and three patients had their body mass index (BMI) increased during the treatment, but not reaching the overweight category.

###### 

General data from 22 patients with SMA treated with VPA.

  Case   Age/sex   SMA type   Age at diagnosis   Maximal motor ability   Procedures
  ------ --------- ---------- ------------------ ----------------------- -----------------------------------------
  1      9y/F      II         8y                 Sits                    \-\-\-\-\-\-\-\-\-\-\--
  2      3y/F      II         1y                 Sits                    \-\-\-\-\-\-\-\-\-\-\--
  3      5y/M      III        4y                 Walks independently     \-\-\-\-\-\-\-\-\-\-\--
  4      6y/M      III        2y                 Walks independently     \-\-\-\-\-\-\-\-\-\-\--
  5      18y/F     III        4y                 Walks independently     \-\-\-\-\-\-\-\-\-\-\--
  6      3y/F      II         1y                 Sits                    \-\-\-\-\-\-\-\-\-\-\--
  7      13y/M     III        4y                 Walks independently     \-\-\-\-\-\-\-\-\-\-\--
  8      2y/F      III        2y                 Walks independently     \-\-\-\-\-\-\-\-\-\-\--
  9      6y/M      II         3y                 Stand up with support   Foot and spinal orthesis
  10     5y/M      II         10 mo              Sits                    \-\-\-\-\-\-\-\-\-\--
  11     15y/F     II         2y                 Sits                    Back surgery
  12     5y/M      III        4y                 Walks independently     \-\-\-\-\-\-\-\-\-\--
  13     13y/F     II         3y                 Sits                    Back surgery
  14     3y/F      III        8 mo               Walks independently     \-\-\-\-\-\-\-\-\-\--
  15     3y/M      II         1y                 Sits with support       \-\-\-\-\-\-\-\-\-\--
  16     8y/M      III        1y                 Walks independently     \-\-\-\-\-\-\-\-\-\--
  17     15y/F     II         2y                 Sits                    Back and hip surgery
  18     3y/F      II         8 mo               Sits                    Spinal orthesis
  19     11y/M     II         1y                 Sits                    Foot orthesis
  20     2y/M      II         2y                 Sits with support       Foot orthesis/BiPAP
  21     4y/M      III        1y                 Walks independently     Foot orthesis
  22     16y/M     II         7y                 Sits with support       \-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

F = female, m = male, y = year, mo = months

Muscle strength, the HFMS and the Barthel index
-----------------------------------------------

The comparison between the MRC mean in the first evaluation and in subsequent ones did not show any significant difference (p \> 0.05) (Table [2](#T2){ref-type="table"}). The analysis of all 22 patients together showed a significant difference in the HFMS scores comparing the first with the second and the fourth evaluations (p = 0.038 and p = 0.039, respectively), but not in the third and fifth evaluations. The group of children with SMA type II presented a significant gain in HFMS score comparing the first evaluation with the subsequent ones (p = 0.031) (Table [3](#T3){ref-type="table"}). This gain in HFMS score was not observed in the group of type III patients (p = 0.961). Patients younger than six years of age had a better mean score on HFMS than the group older than six years of age (Table [4](#T4){ref-type="table"}). However, the comparison of the HFMS score of the first evaluation with the subsequent ones in the groups of patients younger and older than 6 years of age did not show any significant result (p = 0.240 and p = 0.922, respectively) (Table [4](#T4){ref-type="table"}). According to the Table [2](#T2){ref-type="table"}, there was a significant difference when comparing the mean of the Barthel score of the first evaluation with the fourth and fifth evaluations, indicating an improvement of the daily activities at the end of the VPA treatment period.

###### 

Comparison between the mean of the MRC, HFMS and Barthel index scores in the first evaluation and the subsequent evaluations in the 22 SMA patients treated with VPA.

  Evaluation   MRC                      HFMS                     Barthel
  ------------ ------------------------ ------------------------ ------------------------
  1 × 2        -0.0 ± 0.4 (p = 0.999)   -0.8 ± 0.4 (p = 0.038)   -0.0 ± 0.7 (p = 0.999)
  1 × 3        -0.1 ± 0.6 (p = 0.947)   -1.0 ± 0.5 (p = 0.056)   -1.3 ± 0.9 (p = 1.53)
  1 × 4        -0.4 ± 0.7 (p = 0.600)   -1.4 ± 0.6 (p = 0.039)   -2.3 ± 1.1 (p = 0.043)
  1 × 5        -1.0 ± 0.8 (p = 0.267)   -1.4 ± 0.7 (0.063)       -2.7 ± 1.3 (p = 0.045)

###### 

Evolution of the HFMS scores in the two SMA groups (type II and III) during the VPA treatment.

             Evaluations                                                           
  ---------- ------------- ------------- ------------- ------------- ------------- -------
  Type II    13.6 ± 10.0   14.9 ± 11.4   15.5 ± 11.1   16.0 ± 11.2   16.9 ± 10.6   0.031
  Type III   24.9 ± 3.4    24.8 ± 3.3    24.4 ± 3.5    24.4 ± 3.5    24.1 ± 3.9    0.961
  p (\*\*)   0.006         0.016         0.029         0.039         0.051         

\* Comparison between the first evaluation with the subsequent ones

\*\* Comparison between both groups (type II and III) in each evaluation

###### 

Evolution of the HFMS scores in the two age groups of SMA patients during the VPA treatment.

               Evaluations                                                       
  ------------ ------------- ------------ ------------ ------------ ------------ -------
  ≤ 6 years    21.5 ± 8.8    22.5 ± 9.5   22.9 ± 8.7   23.2 ± 8.3   23.5 ± 8.7   0.240
  \> 6 years   12.2 ± 8.8    12.7 ± 9.0   12.8 ± 9.0   13.0 ± 9.2   12.8 ± 9.1   0.922
  p (\*\*)     0.018         0.012        0.010        0.009        0.007        

\* Comparison between the first evaluation with the subsequent ones

\*\* Comparison between both groups of patients in each evaluation

Discussion
==========

Our present study demonstrated that there was not any evident motor function deterioration during the period of one year of treatment with VPA in patients with SMA type II and III. We did not detect any significant change in muscular strength tested using the MRC scale. However, we observed a significant improvement in the motor abilities assessed by HFMS, a scale that was structured and validated specifically for evaluating children with SMA \[[@B23]\]. When all 22 patients were analyzed together, the comparison of the first HFMS score with the following ones showed a significant improvement only in the second and fourth evaluations, but not in the third and fifth ones, suggesting that treatment with VPA might produce variable pick of action. Another way, when both groups of SMA (type II and type III) were analyzed separately, there was a significant gain on HFMS score comparing the first evaluation with the subsequent ones only in the SMA type II group.

The major limitation of our study was the non inclusion of a control group. Despite suffering from a progressive neurodegenerative disease, patients with SMA type II/III may show short term improvement of their motor status, in which it could be influenced by many factors including physical therapy, mental status and systemic diseases. However, in the period of evaluation, we could observe that no patient presented deterioration of their motor function, in which it would be expected considering the progressive course of the disease.

In our study, we did not perform *SMN2*mRNA level analysis. However, studies assessing *SMN*mRNA levels in treated patients with VPA have demonstrated conflicting results. Brichta et al \[[@B17]\] observed elevated *SMN2*mRNA levels in seven patients with SMA treated with VPA and unchanged or decreased levels in thirteen patients. Swoboda et al \[[@B20]\] did not show any significant increase of *SMN*2 mRNA levels in children treated with VPA, although the level of mRNA fluctuated throughout VPA treatment, in contrast with untreated patients in which the level was fairly stable, indicating that at least some response to the VPA treatment was obtained.

In this study we included only SMA patients with types II and III, avoiding the inclusion of the most severe form of the disease (type I). However, unfortunately we did not measure the *SMN2*copy number in our patients that would be very interesting to divide the patients in more homogeneous groups and for a better comparison of our results with future studies.

According to Swoboda et al \[[@B26]\] the best potential gain from therapeutic intervention, if any, should be more probable in pre-clinic phases when the children have a large number of still healthy motor neurons, thereby allowing for more benefits. Swoboda et al (2009) \[[@B20]\] showed a significant improvement that was almost restricted to participants less than 5 years of age following VPA treatment in 42 patients with SMA. In our study, patients younger than six years of age had a better mean score on HFMS than the group older than six years of age, however, the comparison of the HFMS score of the first evaluation with the subsequent ones in the both groups (younger and older than 6 years of age) did not show significant differences. Moreover, in our study we observed a significant improvement of the HFMS scores during the VPA treatment in the group of type II children but not in the type III group, differently of the study of Weihl et al \[[@B18]\] that showed a more efficacious of VPA treatment in adult SMA patients than in younger ones with a more severe phenotype.

We routinely added L-carnitine to VPA therapy as there are numerous references to the potential benefit of this drug in preventing or even treating a possible hepatotoxicity of VPA due to its interference with mitochondrial beta-oxidation \[[@B27]-[@B30]\]. In addition VPA monotherapy depletes both muscle and serum carnitine levels \[[@B30]\]. Side effects were unremarkable in our study. Five patients complained of weight gain, and other patients displayed increased tremor of their fingers after six months of VPA intake, as observed by Tsai et al \[[@B19]\] in one 5-years-old child.

Conclusion
==========

Patients with type II and III SMA submitted to treatment with VPA during the period of one year had no significant side effects, and an increased of the motor abilities could be observed in children with type II SMA. Treatment of SMA patients with VPA may be a potential alternative to alleviate the progression of the disease.
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